NASDAQ
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
Open
$70.74
Previous Close
$70.75
Day High
$70.76
Day Low
$70.13
52 Week High
$83.86
52 Week Low
$12.30
No price data available for this timeframe.